

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.  
Substitute for form 1449/PTO
**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Use as many sheets as necessary)
**Complete if Known**

Application Number	10/696,639
Filing Date	10/29/2003
First Named Inventor	Maureen J. Bourner
Art Unit	1632
Examiner Name	TBA
Attorney Docket Number	PC27428A

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	Cite No. <sup>1</sup>	DOCUMENT NUMBER	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup>			
	AA	3,687,808	08-29-1972	Merigan, Jr. T., et al	
	AB	4,179,337	12-19-1979	Davis, F., et al	
	AC	4,301,144	11-17-1981	Iwashita, Y., et al	
	AD	4,426,330	01-17-1984	Sears.B.	
	AE	4,469,863	09-04-1984	Ts'o, P., et al	
	AF	4,476,301	10-09-1984	Imbach, J., et al	
	AG	4,485,045	11-27-1984	Regen, S.	
	AH	4,496,689	01-29-1985	Mitra, G.,	
	AI	4,534,899	08-13-1985	Sears, B.	
	AJ	4,544,545	10-01-1985	Ryan, P., et al	
	AK	4,587,044	05-06-1986	Miller, P., et al	
	AL	4,605,735	08-12-1986	Miyoshi, K., et al	
	AM	4,640,835	02-03-1987	Shimizu, K., et al	
	AN	4,667,025	05-19-1987	Miyoshi, K., et al	
	AO	4,670,417	06-02-1987	Iwashita, Y., et al	
	AP	4,676,980	06-30-1987	Segal, D., et al	
	AQ	4,683,195	07-28-1987	Mullis, K., et al	

EXAMINER:

DATE CONSIDERED:

12/14/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). <sup>2</sup>See Kinda Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**Complete if Known**

Application Number	10/696,639
Filing Date	10/29/2003
First Named Inventor	Maureen J. Bourner
Art Unit	1632
Examiner Name	TBA
Attorney Docket Number	PC27428A

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Use as many sheets as necessary)

<i>[Signature]</i>	AR	4,683,202	07-28-1987	Mullis, K.,	
	AS	4,736,866	04-12-1988	Leder, P., et al	
	AT	4,737,323	04-12-1988	Martin, F., et al	
	AU	4,762,779	08-09-1988	Snitman, D., et al	
	AV	4,789,737	12-06-1988	Miyoshi, K., et al	
	AW	4,791,192	12-13-1988	Nakagawa, Y., et al	
	AX	4,816,567	03-28-1989	Cabilly, S., et al.	
	AY	4,824,941	04-25-1989	Gordon, J., et al	
	AZ	4,828,979	05-09-1989	Klevan, L., et al	
	BA	4,835,263	05-30-1989	Nguyen, T., et al	
	BB	4,837,028	06-06-1989	Allen, T.	
	BC	4,845,205	07-04-1989	Dinh, T., et al	
	BD	4,870,009	09-26-1989	Evans, R., et al	
	BE	4,873,191	10-10-1989	Wagner, T., et al	
	BF	4,876,335	10-24-1989	Yamane, A., et al	
	BG	4,904,582	02-27-1990	Tullis, R., et al	
	BH	4,948,882	08-14-1990	Ruth, J.	
	BI	4,958,013	09-18-1990	Letsinger, R.	
<i>[Signature]</i>	BJ	4,981,957	01-01-1991	Lebleu, B., et al	
	BK	5,013,556	05-07-1991	Woodle, M., et al	

EXAMINER:

DATE CONSIDERED:

*12/14/05*

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinda Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO

**Complete if Known**

Application Number	10/696,639
Filing Date	10/29/2003
First Named Inventor	Maureen J. Bourner
Art Unit	1632
Examiner Name	TBA
Attorney Docket Number	PC27428A

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

BL	5,013,830	05-07-1991	Ohtsuka, E., et al	
BM	5,023,243	06-11-1991	Tullis, R.	
BN	5,034,506	07-23-1991	Summerton, J., et al	
BO	5,082,830	01-21-1992	Brakel, C., et al	
BP	5,093,531	03-03-1992	Sano, A., et al	
BQ	5,109,124	04-28-1992	Ramachandran, K., et al	
BR	5,108,921	04-28-1992	Low, P., et al	
BS	5,112,963	05-12-1992	Pieles, Uwe, et al	
BT	5,118,800	06-02-1992	Smith, L., et al	
BU	5,118,802	06-02-1992	Smith, L., et al;	
BV	5,122,614	06-16-1992	Zalipsky, S.	
BW	5,130,302	07-14-1992	Spielvogel, B., et al	
BX	5,134,066	07-28-1992	Rogers, T., et al;	
BY	5,138,045	08-11-1992	Cook, P., et al	
BZ	5,149,797	09-22-1992	Pederson, T., et al	
CA	5,166,315	11-24-1992	Summerton, J., et al	
CB	5,175,273	12-29-1992	Bischofberger, N., et al	
CC	5,177,196	01-05-1993	Meyer, Jr., R., et al	
CD	5,185,444	02-09-1993	Summerton, J. et al	
CE	5,188,897	02-23-1993	Suhadolnik, R., et al	

EXAMINER:

DATE CONSIDERED:

12/15/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.16). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO

**Complete if Known**

Application Number	10/696,639
Filing Date	10/29/2003
First Named Inventor	Maureen J. Bourner
Art Unit	1632
Examiner Name	TBA
Attorney Docket Number	PC27428A

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

CF	5,214,134	05-25-1993	Weis, A., et al
CG	5,214,136	05-25-1993	Lin, Kuei-Ying, et al
CH	5,213,804	05-25-1993	Martin, F., et al
CI	5,216,141	06-01-1993	Benner, S., et al
CJ	5,218,105	06-08-1993	Cook, P., et al
CK	5,220,007	06-15-1993	Pederson, T., et al
CL	5,227,170	07-13-1993	Sullivan, S.
CM	5,235,033	08-10-1993	Summerton, J., et al
CN	5,245,022	09-14-1993	Weis, A., et al
CO	5,254,469	10-19-1993	Warren, H., et al
CP	5,256,775	10-26-1993	Froehler, Brian C.
CQ	5,258,506	11-02-1993	Urdea, M., et al
CR	5,262,536	11-16-1993	Hobbs, Jr., F.
CS	5,264,423	11-23-1993	Cohen, J., et al
CT	5,264,562	11-23-1993	Matteucci, M., et al
CU	5,264,564	11-23-1993	Matteucci, M., et al
CV	5,264,221	11-23-1993	Tagawa, T., et al
CW	5,272,250	12-21-1993	Spielvogel, B., et al
CX	5,276,019	01-04-1994	Cohen, J., et al
CY	5,278,302	01-11-1994	Caruthers, M., et al

EXAMINER:

DATE CONSIDERED:

12/14/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). <sup>1</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>2</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>5</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.  
Substitute for form 1449/PTO**Complete if Known**

Application Number	10/696,639
Filing Date	10/29/2003
First Named Inventor	Maureen J. Bourner
Art Unit	1632
Examiner Name	TBA
Attorney Docket Number	PC27428A

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

<i>[Signature]</i>	CZ	5,283,317	02-01-1994	Saifer, M., et al	
	DA	5,286,717	02-15-1994	Cohen, J., et al	
	DB	5,292,873	03-08-1994	Rokita, S., et al	
	DC	5,317,098	05-31-1994	Shizuya, H., et al	
	DD	5,319,080	06-07-1994	Leumann, C.	
	DE	5,321,131	06-14-1994	Agrawal, S., et al	
	DF	5,324,844	06-28-1994	Zalipsky, S.	
	DG	5,349,001	09-20-1994	Greenwald, R., et al	
	DH	5,354,844	10-11-1994	Beug, H., et al	
	DI	5,356,633	10-18-1994	Woodle, M., et al	
	DJ	5,359,044	10-25-1994	Cook, P., et al	
	DK	5,367,066	11-22-1994	Urdea, M., et al	
	DL	5,366,878	11-22-1994	Pederson, T., et al	
	DM	5,371,241	12-06-1994	Brush, C.	
	DN	5,391,723	02-21-1995	Priest, J.	
	DO	5,393,878	02-28-1995	Leumann, C.	
	DP	5,395,619	03-07-1995	Zalipsky, S., et al	
	DQ	5,399,676	03-21-1995	Froehler, B.	
<i>[Signature]</i>	DR	5,403,711	04-04-1995	Walder, J., et al	
<i>[Signature]</i>	DS	5,405,877	04-11-1995	Greenwald, R., et al	

EXAMINER:

DATE CONSIDERED:

*12/14/05*

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.


This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
 (Use as many sheets as necessary)
**Complete if Known**

Application Number	10/696,639
Filing Date	10/29/2003
First Named Inventor	Maureen J. Bourner
Art Unit	1632
Examiner Name	TBA
Attorney Docket Number	PC27428A

DT	5,405,939	04-11-1995	Suhadolnik, R., et al	
DU	5,405,938	04-11-1995	Summerton, J., et al	
DV	5,414,077	05-09-1995	Lin, K., et al	
DW	5,416,203	05-16-1995	Letsinger, R.	
DX	5,416,016	05-16-1995	Low, P., et al	
DY	5,417,978	05-23-1995	Tari, A., et al	
DZ	5,428,130	06-27-1995	Capon, D., et al	
EA	5,432,272	07-11-1995	Benner, S.	
EB	5,434,257	07-18-1995	Matteucci, M., et al	
EC	5,446,137	08-29-1995	Maag, H., et al	
ED	5,451,463	09-19-1995	Nelson, P., et al	
EE	5,453,496	09-26-1995	Caruthers, M., et al	
EF	5,455,233	10-03-1995	Spielvogel, B., et al	
EG	5,457,187	10-10-1995	Gmeiner, W., et al	
EH	5,459,255	10-17-1995	Cook, P., et al	
EI	5,459,127	10-17-1995	Felgner, P., et al	
EJ	5,462,854	10-31-1995	Coassin, P., et al	
EK	5,466,677	11-14-1995	Baxter, A., et al	
EL	5,466,786	11-14-1995	Buhr, C., et al	
EM	5,469,854	11-28-1995	Unger, E., et al	

EXAMINER:		DATE CONSIDERED:	12/14/05
-----------	---	------------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kindof Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kindof document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**Complete if Known**

Application Number	10/696,639
Filing Date	10/29/2003
First Named Inventor	Maureen J. Bourner
Art Unit	1632
Examiner Name	TBA
Attorney Docket Number	PC27428A

**INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

	EN	5,470,967	11-28-1995	Huie, E., et al	
	EO	5,476,925	12-19-1995	Letsinger, R., et al	
	EP	5,484,908	01-16-1996	Froehler, B., et al	
	EQ	5,486,603	01-23-1996	Buhr, C.	
	ER	5,489,677	02-06-1996	Sanghvi, Y., et al	
	ES	5,491,133	02-13-1996	Walder, J., et al	
	ET	5,498,531	03-12-1996	Jarrell, K.	
	EU	5,502,177	03-26-1996	Matteucci, M., et al	
	EV	5,510,475	04-23-1996	Agrawal, S. et al	
	EW	5,512,439	04-30-1996	Hornes, E., et al	
	EX	5,512,667	04-30-1996	Reed, M., et al	
	EY	5,512,295	04-30-1996	Komberg, A., et al	
	EZ	5,514,545	05-07-1996	Eberwine, J.	
	FA	5,514,785	05-07-1996	Van Ness, J., et al	
	FB	5,519,126	05-21-1996	Hecht, S.	
	FC	5,519,134	05-21-1996	Acevedo, O., et al	
	FD	5,521,291	05-28-1996	Curiel, D., et al	
	FE	5,525,711	06-11-1996	Hawkins, M., et al	
	FF	5,525,465	06-11-1996	Haralambidis, J., et al	
	FG	5,527,528	06-18-1996	Allen, T., et al	

EXAMINER:

DATE CONSIDERED:

12/14/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.


This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
 (Use as many sheets as necessary)
**Complete if Known**

Application Number	10/696,639
Filing Date	10/29/2003
First Named Inventor	Maureen J. Bourner
Art Unit	1632
Examiner Name	TBA
Attorney Docket Number	PC27428A

	FH	5,534,259	07-09-1996	Zalipsky, S., et al	
	FI	5,536,821	07-16-1996	Agrawal, S., et al	
	FJ	5,539,082	07-23-1996	Nielsen, P., et al	
	FK	5,541,306	07-30-1996	Agrawal, S., et al;	
	FL	5,541,313	07-30-1996	Ruth, J.	
	FM	5,541,307	07-30-1996	Cook, P., et al	
	FN	5,543,158	08-06-1996	Gref, R., et al	
	FO	5,543,152	08-06-1996	Webb, M., et al	
	FP	5,545,522	08-13-1996	Van Gelder, R., et al	
	FQ	5,545,807	08-13-1996	Surani, A., et al	
	FR	5,545,806	08-13-1996	Lonberg, N., et al	
	FS	5,545,730	08-13-1996	Urdea, M., et al	
	FT	5,547,932	08-20-1996	Curiel, D., et al	
	FU	5,550,111	08-27-1996	Suhadolnik, R., et al	
	FV	5,552,540	09-03-1996	Haralambidis, J.	
	FW	5,552,538	09-03-1996	Urdea, M., et al	
	FX	5,556,948	09-17-1996	Tagawa, T., et al;	
	FY	5,561,225	10-01-1996	Maddry, J. et al	
	FZ	5,563,253	10-08-1996	Agrawal, S., et al	
	GA	5,565,552	10-15-1996	Magda, D., et al	

EXAMINER:

DATE CONSIDERED:

12/14/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kinds of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
 (Use as many sheets as necessary)
**Complete if Known**

Application Number	10/696,639
Filing Date	10/29/2003
First Named Inventor	Maureen J. Bourner
Art Unit	1632
Examiner Name	TBA
Attorney Docket Number	PC27428A

GB	5,565,350	10-15-1996	Kmiec, E.,	
GC	5,567,811	10-22-1996	Misiura, K., et al	
GD	5,567,810	10-22-1996	Weis, A., et al	
GE	5,569,825	10-29-1996	Lonberg, N., et al	
GF	5,571,799	11-05-1996	Tkachuk, Z., et al	
GG	5,574,142	11-12-1996	Meyer, Jr., R., et al	
GH	5,576,427	11-19-1996	Cook, P., et al	
GI	5,578,717	11-26-1996	Urdea, M., et al	
GJ	5,578,718	11-26-1996	Cook, P., et al	
GK	5,580,731	12-03-1996	Chang, C., et al	
GL	5,580,575	12-03-1996	Unger, E., et al	
GM	5,583,020	12-10-1996	Sullivan, S.	
GN	5,585,481	12-17-1996	Arnold, Jr., L., et al	
GO	5,587,361	12-24-1996	Cook, P., et al	
GP	5,587,469	12-24-1996	Cook, P., et al	
GQ	5,587,371	12-24-1996	Sessler, J., et al	
GR	5,591,722	01-07-1997	Montgomery, J., et al	
GS	5,591,584	01-07-1997	Chang, C., et al	
GT	5,591,721	01-07-1997	Agrawal, s., et al	
GU	5,596,091	01-21-1997	Switzer, C.	

EXAMINER:

DATE CONSIDERED:

12/14/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kindof Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kindof document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Use as many sheets as necessary)**Complete if Known**

Application Number	10/696,639
Filing Date	10/29/2003
First Named Inventor	Maureen J. Bourner
Art Unit	1632
Examiner Name	TBA
Attorney Docket Number	PC27428A

GV	5,595,726	01-21-1997	Magda, D., et al	
GW	5,595,756	01-21-1997	Bally, M., et al	
GX	5,596,086	01-21-1997	Matteucci, M., et al	
GY	5,597,909	01-28-1997	Urdea, M., et al	
GZ	5,597,696	01-28-1997	Linn, C., et al	
HA	5,599,928	02-04-1997	Hemmi, G., et al	
HB	5,599,923	02-04-1997	Sessler, J., et al	
HC	5,602,240	02-11-1997	Mesmaeker, A., et al	
HD	5,608,046	03-04-1997	Cook, P., et al	
HE	5,610,300	03-11-1997	Altmann, K., et al	
HF	5,610,289	03-11-1997	Cook, P., et al	
HG	5,612,640	03-18-1997	Murabayashi, F., et al	
HH	5,614,617	03-25-1997	Cook, P., et al	
HI	5,618,704	04-08-1997	Sanghvi, Y., et al	
HJ	5,623,065	04-22-1997	Cook, P., et al	
HK	5,623,070	04-22-1997	Cook, P., et al	
HL	5,625,126	04-29-1997	Lonberg, N., et al	
HM	5,625,050	04-29-1997	Beaton, G., et al	
HN	5,627,053	05-06-1997	Usman, N., et al	
HO	5,633,425	05-27-1997	Lonberg, N., et al	

EXAMINER:

DATE CONSIDERED:

12/14/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kindof document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
 (Use as many sheets as necessary)
**Complete if Known**

Application Number	10/696,639
Filing Date	10/29/2003
First Named Inventor	Maureen J. Bourner
Art Unit	1632
Examiner Name	TBA
Attorney Docket Number	PC27428A

HP	5,633,360	05-27-1997	Bischofberger, N., et al	
HQ	5,639,873	06-17-1997	Barascut, J., et al	
HR	5,646,265	07-08-1997	McGee, D.	
HS	5,652,355	07-29-1997	Metelev, V., et al	
HT	5,652,356	07-29-1997	Agrawal, S.	
HU	5,658,873	08-19-1997	Bertsch-Frank, B., et al	
HV	5,661,016	08-26-1997	Lonberg, N., et al	
HW	5,663,312	09-02-1997	Chaturvedula, P.	
HX	5,670,633	09-23-1997	Cook, P., et al	
HY	5,677,437	10-14-1997	Teng, K., et al	
HZ	5,677,439	10-14-1997	Weis, A., et al	
IA	5,681,941	10-28-1997	Cook, P., et al	
IB	5,688,941	11-18-1997	Cook, P., et al	
IC	5,700,920	12-23-1997	Altmann, K., et al	
ID	5,700,922	12-23-1997	Cook, P.	
IE	5,714,331	02-03-1998	Buchardt, O., et al	
IF	5,719,262	02-17-1998	Borchardt, O., et al	
IG	5,750,692	05-12-1998	Cook, P., et al	
IH	5,824,784	10-20-1998	Kinstler, O., et al	
II	5,981,733	11-09-1999	Gamble, R., et al	

EXAMINER:

DATE CONSIDERED:

12/14/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.1). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
 (Use as many sheets as necessary)
**Complete if Known**

Application Number	10/696,639
Filing Date	10/29/2003
First Named Inventor	Maureen J. Bourner
Art Unit	1632
Examiner Name	TBA
Attorney Docket Number	PC27428A

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	Cite No. <sup>1</sup>	Foreign Patent Document <sup>2</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
R	IJ	Abstract of EP 0 133 988				
	IK	Abstract of EP 0 052 322				
	IL	Abstract of EP 0 102 324		Ciba-Geigy AG		
	IM	EP 0 36 676	09-30-1981	The Regents of the University of California		
	IN	EP 0 52 322	11-09-1981	Folia Bioch. Et Biol. Graeca		
	IO	EP 0 88 046	02-11-1983	Ciba-Geigy AG		
	IP	EP 0 102 324	07-25-1983	Ciba-Geigy AG		
	IQ	EP 0 133 988	08-01-1984	Hoechst Aktiengesellschaft		
	IR	EP 0 142 641	08-24-1984	Dr. Udo Ehrenfeld		
	IS	WO84/03564	09-13-1984	Commonwealth Serum Laboratories commission		
	IT	EP 0 143 949	06-12-1985	Terumo Kabushiki Kaisha		
	IU	US 4,619,794 (English Equiv. of EP 0 88 046)	10-28-1986	Ciba-Geigy Corporation		
	IV	WO87/05330	09-11-1987	Michael Bergh, et al.		
	IW	EP 0 307 247	03-15-1989	Genentech, Inc.		
	IX	WO89/06692	07-27-1989	Genentech, Inc.		
	IY	EP 0 404 097	06-20-1990	Behringwerke Aktiengesellschaft		
	IZ	WO91/00360	01-10-1991	Medarex, Inc.		

EXAMINER:

DATE CONSIDERED:

12/14/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kinds of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**Complete if Known**

Application Number	10/696,639
Filing Date	10/29/2003
First Named Inventor	Maureen J. Bourner
Art Unit	1632
Examiner Name	TBA
Attorney Docket Number	PC27428A

**INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

JA	US 5,021,234 (English Equiv. of EP 0 142 641)	06-04-1991	Udo Ehrenfeld		
JB	WO92/00373	01-09-1992	Biosource Genetics Corporation		
JC	WO92/22653	12-23-1992	Genentech, Inc.		
JD	WO93/08829	05-13-1993	The Regents of the University of California		
JE	WO93/11161	06-10-1993	Enzon, Inc.		
JF	WO94/10300	05-11-1994	The General Hospital Corporation		
JG	WO94/11026	05-26-1994	Idec Pharmaceuticals Corporation		
JH	WO94/16101	07-21-1994	Hubert Koster		
JI	WO95/35505	12-28-1995	The Board of Trustees of the Leland Stanford Junior University		
JJ	WO96/27011	09-06-1996	Genentech, Inc.		
JK	US 5,591,828 (English Equiv. of EP 0 404 097)	01-01-1997	Behringwerke Aktiengesellschaft		
JL	WO97/07668	03-06-1997	Roslin Institute		
JM	WO97/07669	03-06-1997	Roslin Institute		
JN	WO97/33551	09-18-1997	Millennium Pharmaceuticals		
JO	EP 0 439 508	04-08-1998	PolyMASC Pharmaceuticals		
JP	EP 0 714 402	11-15-2000	PolyMASC Pharmaceuticals, plc		
JQ	EP 0 257 956	11-22-2000	Genentech, Inc.		

EXAMINER:

DATE CONSIDERED:

12/14/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
 (Use as many sheets as necessary)
**Complete if Known**

Application Number	10/696,639
Filing Date	10/29/2003
First Named Inventor	Maureen J. Bourner
Art Unit	1632
Examiner Name	TBA
Attorney Docket Number	PC27428A

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
JR	ALBELDA, S., et al., "Biology Of Disease, Role Of Integrins And Other Cell Adhesion Molecules In Tumor Progression And Metastasis," <i>Laboratory Investigation</i> , 1993, 4-17, vol. 68, no. 1.		
JS	ARAKAWA, F., et al., "Characterization Of A cDNA Clone Encoding A New Species Of The Nonspecific Cross-Reacting Antigen (NCA), A Member Of The CEA Gene Family," <i>BBRC</i> , 1990, 1063-1071, vol. 166, no. 3.		
JT	ARIAZI, E., et al "Identifying Differential Gene Expression In Monoterpene-Treated Mammary carcinomas Using Subtractive Display," <i>The Journal of Biological Chemistry</i> , 1996, 29286-29294, vol. 271, no. 46.		
JU	BARTEL, P., et al., "Elimination Of False Positives That Arise In Using The Two-Hybrid System," <i>BioTechniques</i> , 1993, 920-924, vol. 14, no. 6.		
JV	BENNETT, B., et al., "Molecular Cloning Of A Ligand For The EPH-Related Receptor Protein-Tyrosine Kinase HtK," <i>Proc. Natl. Acad. Sci.</i> , 1995, 1866-1870, vol. 92.		
JW	BERLING, B., et al., "Cloning Of A Carcinoembryonic Antigen Gene Family Member Expressed In Leukocytes Of Chronic Myeloid Leukemia Patients And Bone Marrow," <i>Cancer Research</i> , 1990, 6534-6539, vol. 50.		
JX	BRAXTON, S., et al., "Incorporation Of A Stabilizing Ca <sup>2+</sup> -Binding Loop Into Subtilisin BPN'," <i>Biochemistry</i> , 1992, 7796-7801, vol. 31.		
JY	BRENNAN, M., et al., "Preparation Of Bispecific Antibodies By chemical Recombination Of Monoclonal Immunoglobulin G <sub>1</sub> Fragments," <i>Science</i> , 1985, 81-83, vol. 229.		
JZ	CARON, P., et al., "Engineered Humanized Dimeric Forms Of IgG Are More Effective Antibodies," <i>J. Exp. Med.</i> , 1992, 1191-1195, vol. 176.		
KA	CHEVRAY, P., et al., "Protein Interaction Cloning In Yeast: Identification Of Mammalian Proteins That React With The Leucine Zipper Of Jun ,," <i>Proc. Natl. Acad. Sci., USA</i> , 1992, 5789-5793, vol. 89.		
KB	CHIEN, C., et al., "The Two-Hybrid System: a Method To Identify And Clone Genes For Proteins That Interact With A Protein Of Interest," <i>Proc. Natl. Acad. Sci., USA</i> , 1991, 9578-9582, vol. 88.		
KC	CHO, T., et al., "Isolation Of Opiate Binding Components By Afinity Chromatography And Reconstitution Of Binding Activities," <i>Proc Natl Acad Sci, USA</i> , 1983, 5176-5180, vol. 80.		

EXAMINER:

DATE CONSIDERED:

12/14/05

EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.


Substitute for form 1449/PTO

**Complete if Known**

Application Number	10/696,639
Filing Date	10/29/2003
First Named Inventor	Maureen J. Bourner
Art Unit	1632
Examiner Name	TBA
Attorney Docket Number	PC27428A

**INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

	KD	COONEY, M., et al., "Site-Specific Oligonucleotide Binding Represses Transcription Of The Human c-myc Gene In Vitro," <i>Science</i> , 1988, 456-459, vol. 241.	
	KE	CROOKE, S., et al., "Pharmacokinetic Properties Of Several Novel Oligonucleotide Analogs In Mice," <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 1996, 923-937, vol. 277, no. 2.	
	KF	CROSBY, A., et al., "Genomic Organization Of The Human Osteopontin Gene: Exclusion Of The Locus From A Causative Role In The Pathogenesis Of Dentinogenesis Imperfecta Type II," <i>Genomics</i> , 1995, 155-160, vol. 27.	
	KG	DE LEO, A., et al., "Cell Surface Antigens Of Chemically Induced Sarcomas Of The Mouse," <i>The Journal of Experimental Medicine</i> , 1977, 720, vol. 146.	
	KH	DERVAN, P., et al., "Second Structural Motif For Recognition Of DNA By Oligonucleotide-Directed Triple-Helix Formation," <i>Science</i> , 1991, 1360-1363, vol. 251	
	KI	DURRANT, L., et al., "Immunization Against Tumor Cell Surface Complement-Regulatory Protein," <i>Current Opinion In Investigational Drugs</i> , 2001, 959-966, vol. 2, no. 7.	
	KJ	DYOMIN, V., et al., "MUC1 Is Activated In a B-Cell Lymphoma by the t(1;14)(q21;q32) Translocation And Is Rearranged And Amplified In B-Cell Lymphoma Subsets," <i>Blood</i> , 2000, 2666-2671, vol. 95, no. 8.	
	KK	EPSTEIN, D., et al., "Biological activity Of Liposome-Encapsulated Murine Interferon γ Is Mediated By A Cell Membrane Receptor," <i>Proc. Natl. Acad. Sci. USA</i> , 1985, 3688-3692, vol. 82.	
	KL	EVAN, G., et al., "Isolation Of Monoclonal Antibodies Specific For Human c-myc Proto-Oncogene Product," <i>Molecular And Cellular Biology</i> , 1985, 3610-3616, vol. 5, no. 12.	
	KM	FIELD, J., et al., "Purification Of A RAS-Responsive Adenyl Cyclase Complex From <i>Saccharomyces Cerevisiae</i> By Use Of An Epitope Addition Method," <i>Molecular and. Cellular Biology</i> , 1988, 2159-2165, vol. 8, no. 5.	
	KN	FIELDS, S., et al., "A Novel Genetic System To Detect Protein-Protein Interactions," <i>Nature</i> , 1989, 245-246, vol. 340.	
	KO	FISHWILD, D., et al., "High-Activity Human IgGκ Monoclonal Antibodies From A Novel Strain Of Minilocus Transgenic Mice," <i>Nature Biotechnology</i> , 1996, 845-851, vol. 14.	
	KP	FURGER, K, et al., "The Functional And Clinical Roles Of Osteopontin In Cancer And Metastasis," <i>Current Molecular Medicine</i> , 2001, 621-632, vol. 1, no. 5.	
	KQ	FURUSE, M., et al., "Claudin-1 And -2: Novel Integral Membrane Proteins Localizing At tight Junctions With No Sequence Similarity To Occludin," <i>The Journal of Cell Biology</i> , 1998, 1539-1550, vol. 141, no. 7.	

EXAMINER:

DATE CONSIDERED:

12/14/05


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.


This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
 (Use as many sheets as necessary)
**Complete if Known**

Application Number	10/696,639
Filing Date	10/29/2003
First Named Inventor	Maureen J. Bourner
Art Unit	1632
Examiner Name	TBA
Attorney Docket Number	PC27428A

	KR	GABIZON, A., et al., "Pharmacokinetics And Tissue Distribution Of Doxorubicin Encapsulated In Stable Liposomes With Long Circulation Times," <i>Journal Of The National Cancer Institute</i> , 1989, 1484-1488, vol. 81, no. 19.	
	KS	GAMALLO, C., et al., "The Prognostic Significance Of P-Cadherin In Infiltrating Ductal Breast Carcinoma," <i>Modern Pathology</i> , 2001, 650-654, vol. 14, no. 7.	
	KT	GENDLER, S., et al., "Molecular Cloning And Expression Of Human Tumor-Associated Polymorphic Epithelial Mucin," <i>The Journal of Biological Chemistry</i> , 1990, 15286-15293, vol. 265, no. 25.	
	KU	GORTER, A., et al., "Immune Evasion Of Tumor Cells Using Membrane-Bound Complement Regulatory Proteins," <i>Immunology Today</i> , 1999, 576-582, vol. 20.	
	KV	GRUBER, M., et al., "Efficient Tumor Cell Lysis Mediated By A Bispecific Single Chain Antibody Expressed In <i>Escherichia Coli</i> ," <i>The Journal of Immunology</i> , 1994, 5368-5374, vol. 152.	
	KW	GRUNDEMANN, D., et al., Molecular Identification Of The Corticosterone-Sensitive Extraneuronal Catecholamine Transporter," <i>Nature Neuroscience</i> , 1998, 349-341, vol. 1, no. 5.	
	KX	HAGGERTY, J., et al., "Identification And Characterization Of A Cell Surface Proteoglycan On Keratinocytes," <i>The Journal of Investigative Dermatology</i> , 1992, 374-380, vol. 99, vol. 4.	
	KY	HANAHAN, D., et al, "The Hallmarks of Cancer," <i>Cell</i> , 2000, 57-70, vol. 100.	
	KZ	HART, K., et al., "Identification Of Tyrosine Residues In Constitutively Activated Fibroblast Growth Factor Receptor 3 Involved In Mitogenesis, Stat Activation, And Phosphatidylinositol 3-Kinase Activation," <i>Molecular Biology Of The Cell</i> , 2001, 931-941, vol. 12.	
	LA	HENSEL, F., et al., "Regulation Of The New Coexpressed CD55 (Decay-Accelerating Factor) Receptor On Stomach Carcinoma Cells Involved In Antibody SC-1-Induced Apoptosis," <i>Laboratory Investigation</i> , 2001, 1553-1563, vol. 81, no. 11.	
	LB	HOLLIGER, P., "Diabodies": Small Bivalent And Bispecific Antibody Fragments," <i>Proc. Natl. Acad. Sci. USA</i> , 1993, 6444-6448, vol. 90.	
	LC	HOPP, T., et al., "A Short Polypeptide Marker Sequence Useful For Recombinant Protein Identification And Purification," <i>Bio/Technology</i> , 1988, 1204-1210, vol. 6.	
	LD	HOWARD, M., et al., "Intracerebral Drug Delivery In Rats With Lesion-Induced Memory Deficits," <i>J Neurosurg</i> 1989, 105-112, vol. 71.	
	LE	HUBER, B., et al., "In Vivo Antitumor Activity Of 5-Fluorocytosine On Human Colorectal Carcinoma Cells Genetically Modified To Express cytosine Deaminase," <i>Cancer Research</i> , 1993, 4619-4626, vol. 53.	

EXAMINER:		DATE CONSIDERED:	12/14/05
-----------	---	------------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
 (Use as many sheets as necessary)
**Complete if Known**

Application Number	10/696,639
Filing Date	10/29/2003
First Named Inventor	Maureen J. Bourner
Art Unit	1632
Examiner Name	TBA
Attorney Docket Number	PC27428A

LF	HUBERT, R., et al, "STEAP: a Prostate-Specific Cell-Surface Antigen Highly Expressed In Human Prostate Tumors," <i>Proc. Natl Acad Sci.</i> , 1999, 14523-14528, vol. 96, no. 25.
LG	ICHTCHENKO, K., et al., "Neuroligin 1: A Splice Site-Specific Ligan For β-Neurexins," <i>Cell</i> , 1995, 435-443, vol. 81.
LH	ISMAIL, R., et al., "Differential Gene Expression Between Normal And Tumor-Derived Ovarian Epithelial Cells <sup>1</sup> ," <i>Cancer Research</i> , 2000, 6744-6749, vol. 60.
LI	IWABUCHI, K., et al., "Use Of The Two-Hybrid System To Identify The Domain Of p53 Involved In Oligomerization , " <i>Oncogene</i> , 1993, 1693-1696, vol. 8.
LJ	JOLIOT, A., et al., "Antennapedia Homeobox Peptide Regulates Neural Morphogenesis," <i>Proc. Natl. Acad. Sci., USA</i> , 1991, 1864-1868, vol. 88.
LK	KABANOV, A., et al., "A New Class Of Antivirals: Antisense Oligonucleotides Combined With A Hydrophobic Substituent Effectively Inhibit Influenza Virus Reproduction And Synthesis Of Virus-Specific Protein In MDCK Cells," <i>FEBS Letters</i> , 1990, 327-330, vol. 259, no. 2.
LL	KARLSSON, S., et al., "A Genetic Polymorphism Of A Human Urinary Mucin," <i>Ann. Hum Genet.</i> , 1983, 263-269, vol. 47.
LM	KIKUNO, R., et al., "Prediction Of The Coding Sequences Of Unidentified Human Genes. XIV. The Complete Sequences Of 100 New cDNA Clones From Brain Which Code For Large Proteins <i>In Vitro</i> ," <i>DNA Research</i> , 1999, 197-205, vol. 6.
LN	KINUGASA, T., "Claudins Regulate The Intestinal Barrier In Response To Immune Mediators," <i>Gastroenterology</i> , 2000, 1001-1011, vol. 118, no. 6.
LO	KOLODNER, R., "Biochemistry And Genetics Of Eukaryotic Mismatch Repair," <i>Genes and Development</i> , 1996, 1433-1442, vol. 10.
LP	KORETZ, K., et al., "Decay-Accelerating Factor(DAF, CD55) In Normal Colorectal Mucosa, Adenomas And Carcinomas," <i>Br. J. Cancer</i> , 1992, 810-814, vol. 66.
LQ	KOSTELNY, S., et al., "Formation Of A bispecific Antibody By The Use Of Leucine Zippers," <i>The Journal of Immunology</i> , 1992, 1547-1553, vol. 148, no. 5.
LR	KRAMER, F., et al., "Genomic Organization Of Claudin-1 And Its Assessment In Hereditary And Sporadic Breast Cancer," <i>Hum Genet</i> , 2000, 249-256, vol. 107.
LS	KROGH, A., et al., "Predicting Transmembrane Protein Topology With a Hidden Markov Model: Application To Complete Genomes," <i>J. Mol. Bio.</i> , 2001, 567-580, vol.305.

EXAMINER:

DATE CONSIDERED:

12/14/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
 (Use as many sheets as necessary)
**Complete if Known**

Application Number	10/696,639
Filing Date	10/29/2003
First Named Inventor	Maureen J. Bourner
Art Unit	1632
Examiner Name	TBA
Attorney Docket Number	PC27428A

<i>JM</i>	LT	LAKSO, M., et al., "Targeted Oncogene Activation By Site-Specific Recombination In Transgenic Mice," <i>Proc. Natl. Acad. Sci., USA</i> , 1992, 6232-6236, vol. 89.
	LU	LAL, A., et al., "A Public Database For Gene Expression In Human Cancers <sup>1</sup> ," <i>Cancer Research</i> , 1999, 5403-5407, vol. 59.
	LV	LAM, K., "Application Of Combinatorial Library Methods In Cancer Research And Drug Discovery," <i>Anticancer Drug Design</i> 1997, 145-167, vol. 12.
	LW	LANDER, E., "The New Genomics: Global views Of Biology," <i>Science</i> , 1996, 536-539, vol. 274, no. 5287.
	LX	LANGER, R., "Controlled Release Of Macromolecules," <i>ChemTech</i> , 1982, 98-105, vol. 12.
	LY	LANGER, R., et al., "Biocompatibility Of Polymeric Delivery Systems For Macromolecules," <i>Journal of Biomedical Materials Research</i> , 1981, 267-277, vol. 15.
	LZ	LEE, J., et al., "Complexes Formed By (pyrimidine) <sub>n</sub> · (purine) <sub>n</sub> DNAs On Lowering The pH Are Three-Stranded," <i>Nucl. Acids Res</i> , 1979, 3073, vol. 6, no. 9.
	MA	LEE, M., et al., "Human KVLT1 Gene Shows Tissue-Specific Imprinting And Encompasses Beckwith-Wiedemann Syndrome Chromosomal rearrangements," <i>Nature Genetics</i> , 1997, 181-185, vol. 15.
	MB	LEONARD, E., et al., "Macrophage Stimulating Protein," <i>Advances In Cancer Research</i> , 2000, 139-165.
	MC	LETSINGER, R., "Cholesteryl-Conjugated Oligonucleotides: Synthesis, Properties, And Activity As Inhibitors Of Replication Of Human Immunodeficiency Virus In Cell Culture," <i>Proc. Natl. Acad. Sci. USA</i> , 1989, 6553-6556, vol. 86.
	MD	LI, E., et al., "Targeted Mutation Of The DNA Methyltransferase Gene Results In Embryonic Lethality," <i>Cell</i> , 1992, 915-926, vol. 69.
	ME	LI, L., et al., "CD55 Is Over-Expressed In The tumour Environment," <i>British Journal of Cancer</i> , 2001, 80-86, vol. 84, no. 1.
	MF	LI, Y., et al., "A Modified Boyden Chamber Assay For Tumor Cell Transendothelial Migration <i>In Vitro</i> ," <i>Clinical and Experimental Metastasis</i> , 1999, 423-429, vol. 17.
<i>V</i>	MG	LIEBNER, S., et al., "Claudin-1 And Claudin-5 Expression And Tight Junction Morphology Are Altered In Blood Vessels Of Human Glioblastoma Multiforme," <i>Acta Neuropathol</i> , 2000, 323-331, vol. 100.

EXAMINER:	<i>JM</i>	DATE CONSIDERED: <i>12/14/05</i>
-----------	-----------	-------------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO

**Complete if Known**

Application Number	10/696,639
Filing Date	10/29/2003
First Named Inventor	Maureen J. Bourner
Art Unit	1632
Examiner Name	TBA
Attorney Docket Number	PC27428A

**INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

<i>[Signature]</i>	MH	LIU, M., et al., "GPR56, A Novel Secretin-Like Human G-Protein-coupled Receptor Gene," <i>Genomics</i> , 1999, 296-305, vol. 55.	
<i>[Signature]</i>	MI	LIU, W., et al., "Coexpression Of Ephrin-Bs And Their Receptors In Colon Carcinoma," <i>Cancer</i> , 2002, 934-939, vol. 94, no. 4.	
	MJ	LONBERG, N., et al., "Human Antibodies from Transgenic Mice," <i>Intern. Rev. Immunol.</i> , 1995, 65-93, vol. 13.	
	MK	LONBERG, N., et al., "Antigen-Specific Human Antibodies From Mice Comprising Four Distinct Genetic Modifications," <i>Nature</i> , 1994, 856-859, no. 368.	
	ML	LUCAS, B., et al., "High-Level Production Of Recombinant Proteins In CHO Cells Using A Dicistrionic DHFR Intron Expression Vector," <i>Nucleic Acids Research</i> , 1996, 1774-1779, vol. 24, no. 9.	
	MM	LUTZ-FREYERMUTH, C., et al., "Quantitative Determination That One Of Two Potential RNA-Binding Domains Of The A Protein Component Of The U1 Small Nuclear Ribonucleoprotein complex Binds With High Affinity To Stem-Loop II Of U1 RNA," <i>Proc. Natl. Acad. Sci., USA</i> , 1990, 6393-6397, vol. 87.	
	MN	MADURA, K., "N-Recognin/Ubc2 Interactions In The N-end Rule Pathway," <i>The Journal of Biological Chemistry</i> , 1993, 12046-12054, vol. 268, no. 16.	
	MO	MAENPAA, A., et al., "Expression Of Complement Membrane Regulators Membrane Cofactor Protein (CD46), Decay Accelerating Factor (CD55), And Protectin (CD59) in Human Malignant Gliomas," <i>American Journal Of Pathology</i> , 1996, 1139-1152, vol. 148, no. 4.	
	MP	MANOHARAN, M., et al., "Oligonucleotide Conjugates: Alteration Of The Pharmacokinetic Properties Of Antisense Agents," <i>Nucleosides &amp; Nucleotides</i> , 1995, 969-973, vol. 14, no. 3-5.	
	MQ	MANOHARAN, M., et al., "Chemical Modifications To Improve Uptake And Bioavailability Of antisense Oligonucleotides," <i>Anal New York Academy of Sciences</i> 1992, 306-309, vol. 660.	
	MR	MANOHARAN, M., et al., "Lipidic Nucleic Acids," <i>Tetrahedron Letters</i> , 1995, 3651-3654, vol. 36, no. 21.	
	MS	MANOHARAN, M., et al., "Cholicacid-Oligonucleotide conjugates for Antisense Applications," <i>Bioorganic Medicinal Chemistry Letters</i> , 1994, 1053-1060, vol. 4, no. 8.	
	MT	MANOHARAN, M., et al., "Introduction Of A Lipophilic Thioether Tether In The Minor Groove Of Nucleic Acids For Antisense Applications," <i>Bioorganic Medicinal Chemistry Letters</i> , 1993, 2765-2770, vol. 3, no. 12.	
<i>[Signature]</i>	MU	MARASCO, W., et al., "Design, Intracellular Expression, And Activity Of A Human Anti-Human Immunodeficiency Virus Type 1 gp120 Single-Chain Antibody," <i>Proc. Natl. Acad. Sci., USA</i> , 1993, 7889-7893, vol. 90.	

EXAMINER:

DATE CONSIDERED:

*12/14/05*

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**Complete if Known**

Application Number	10/696,639
Filing Date	10/29/2003
First Named Inventor	Maureen J. Bourner
Art Unit	1632
Examiner Name	TBA
Attorney Docket Number	PC27428A

**INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

MV	MARKS, J., et al., "By-Passing Immunization: Building High Affinity Human Antibodies By Chain Shuffling," <i>Bio/Technology</i> , 1992, 779-783, vol. 10.
MW	MARTIN, F., et al., "Irreversible coupling Of Immunoglobulin Fragments To Preformed Vesicles," <i>The Journal of Biological Chemistry</i> , 1982, 286-288, vol. 257, no. 1.
MX	MARTIN, G., et al., "GAP Domains Responsible For Ras p21-Dependent Inhibition Of Muscarinic Atrial K <sup>+</sup> Channel Currents," <i>Science</i> , 1992, 192-194, vol. 255.
MY	MEDOF, M., et al., "Cloning And Characterization Of cDNAs Encoding The complete Sequence Of Decay-Accelerating Factor Of Human Complement," <i>Proc. Nat Acad Sci. USA</i> , 1987, 2007-2011, vol. 84.
MZ	MIDGLEY, R., et al., "Colorectal Cancer," <i>The Lancet</i> , 1999, 391-399, vol. 353.
NA	MILSTEIN, C., et al., "Hybrid Hybridomas And Their Use In Immunohistochemistry," <i>Nature</i> , 1983, 537-540, vol. 305.
NB	MISHRA, R., et al., "Improved Leishmanicidal effect Of Phosphorotioate Antisense Oligonucleotides By LDL-Mediated Delivery," <i>Biochimica et Biophysica Acta</i> , 1995, 229-237, vol. 1264.
NC	MODRICH, P., "Mismatch Repair, Genetic Stability And Tumour Avoidance," <i>Phil. Trans. R. Soc. Lond. B</i> , 1995, 89-95, vol. 347.
ND	MORRISON, S., "Success In Specification," <i>Nature</i> , 1994, 812-813, vol. 368.
NE	NAGASE, T., et al., "Prediction Of The coding Sequences Of Unidentified Humlan Genes. XI: The Complete Sequences Of 100 New cDNA Clones From Brain Which Code For Large Proteins In Vitro," <i>DNA Research</i> 1998, 277-286, vol. 5, no. 5.
NF	NIELSEN, P., et al., "Sequence-Selective Recognition Of DNA By Strand Displacement With A Thymine-Substituted Polyamide," <i>Science</i> , 1991, 1497-1500, vol. 254.
NG	NEUBERGER, M., "Generating High-Avidity Human Mabs In Mice," <i>Nature Biotechnology</i> , 1996, 826, vol. 14.
NH	NIEHANS, G., et al., "Human Carcinomas Variably Express The Complement Inhibitory Proteins CD46 (Membrane Cofactor Protein), CD55 (Decay-Accelerating Factor), and CD56 (Protectin)," <i>American Journal of Pathology</i> , 1996, 129-142, vol. 149, no. 1.
NI	NIELSEN, H., et al., "Prediction Of Signal Peptides And Signal Anchors By A Hidden Markov Model" <i>Proceedings Of The Sixth International Conference On Intelligent Systems For Molecular Biology</i> , 1998, 122-130, AAAI Press, Menlo Park, California

EXAMINER:

DATE CONSIDERED:

12/14/08

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.  
Substitute for form 1449/PTO**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Use as many sheets as necessary)**Complete if Known**

Application Number	10/696,639
Filing Date	10/29/2003
First Named Inventor	Maureen J. Bourner
Art Unit	1632
Examiner Name	TBA
Attorney Docket Number	PC27428A

NJ	NOWICKI, S., et al., "Expression Of Decay accelerating factor In Endometrial Adenocarcinoma Is Inversely Related To The Stage Of Tumor," <i>American Journal of Reproductive Immunology</i> , 2001, 144-148, vol. 46.
NK	NYGREN, H., "Conjugation Of Horsradish Peroxidase To Fab Fragments With Different Homobifunctional And Heterobifunctional Cross-Linking reagents," <i>The Journal Of Histochemistry and Cytochemistry</i> , 1982, 407-412, vol. 30, no. 5.
NL	OBERHAUSER, B., et al., "Effective Incorporation Of 2'-O-Methyl-Oligoribonucleotides Into Liposomes And Enhanced Cell Association Through Modification With Thiocholesterol," <i>Nucleic Acids Research</i> , 1992, 533-538, vol. 20, no. 3.
NM	OKANO, H., "Myelin Basic Protein Gene And The Function Of Antisense RNA In Its Repression In Myelin-Deficient Mutant Mouse," <i>Journal of Neurochemistry</i> , 1991, 560-567, vol. 56, no. 2.
NN	PABORSKY, L., et al., "Mammalian Cell Transient Expression Of Tissue Factor For The Production Of Antigen," <i>Protein Engineering</i> , 1990, 547-553, vol. 3, no. 6.
NO	PAIN, D., et al., "Preparation Of Protein A-Peroxidase Monoconjugate Using A Heterobifunctional Reagent, And Its Use In Enzyme Immunoassays," <i>Journal of Immunological Methods</i> , 1981, 219-230, vol. 40.
NP	PANDIT, S., et al., "The Fibroblast Growth Factor Receptor, FGFR3, Forms Gradients Of Intact And Degraded Protein Across The Growth Plate Of Developing Bovine Ribs," <i>Biochem J.</i> , 2002, 231-241, vol. 361.
NQ	PANET, R., et al., "Overexpression Of The Na <sup>+</sup> /K <sup>+</sup> /Cl <sup>-</sup> Cotransporter Gene Induces Cell Proliferation And Phenotypic Transformation In Mouse Fibroblasts," <i>Journal of Cell Physiology</i> , 2000, 109-118, vol. 182.
NR	PAYNE, J., et al., "Primary Structure, Functional Expression, And Chromosomal Localization Of The Bumetanide-Sensitive Na-K-CL Contransporter," <i>The Journal Of Biological Chemistry</i> , 1995, 17977-17985, vol. 270, no. 30.
NS	PILKINGTON, G., "In Vitro And In Vivo Models For The Study Of Brain Tumour Invasion," <i>Anticancer Research</i> , 1997, 4107-4109, vol. 17.
NT	PRICE, N., et al., "Cloning And Sequencing Of Four New Mammalian Monocarboxylate Transporter (MCT) Homologues Confirms The Existence Of A Transporter Family With An Ancient Past," <i>Biochem. J.</i> , 1998, 321-328, vol. 329.
NU	QUAGGIN, S., Localization Of The Renal Na-K-Cl Contransporter Gene ( <i>Slc12a1</i> ) On Mouse Chromosome 2, <i>Mammalian Genome</i> , 1995, 557-561, vol. 6, no. 8.
NV	RAMAMOORTHY, S., et al., "Functional Characterization And Chromosomal Localization Of A Cloned Taurine Transporter From Human Placenta," <i>Biochemical Journal</i> , 1994, 893-900, vol. 300.

EXAMINER:		DATE CONSIDERED:
-----------	---	------------------

12/14/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.


This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
 (Use as many sheets as necessary)
**Complete if Known**

Application Number	10/696,639
Filing Date	10/29/2003
First Named Inventor	Maureen J. Bourner
Art Unit	1632
Examiner Name	TBA
Attorney Docket Number	PC27428A

NW	RIBATTI, D., et al., "The Chick Embryo Chorioallantoic Membrane As A Model for <i>In Vivo</i> Research On Angiogenesis," <i>Intl. J. Dev. Biol.</i> , 1996, 1189-1197, vol. 40.
NX	ROSSI, J., "Making Ribozymes Work In Cells," <i>Current Biology</i> , 1994, 469-471, vol. 4, no. 5.
NY	RUPPERT, S., et al., "Cloning And Expression Of Human TAF- 250: A TBP-Associated Factor Implicated In Cell-Cycle Regulation," <i>Nature</i> , 1993, 175-179, vol. 362.
NZ	RYGAARD, K., et al., "'GROWTH' – A Computer Program For Determination Of Mean Growth Curves And Calculation Of Response To Therapy Of Solid Tumor Xenografts," Proc 6 <sup>th</sup> Int. Workshop On Immune-Deficient Animals, Wu and Sheng eds., 1989, 301-306.
OA	SAISON-BEHMOARAS, T., et al., "Short Modified Antisense Oligonucleotides Directed against Ha-ras Point Mutation Induce Selective cleavage Of The mRNA And Inhibit T24 Cells Proliferation," <i>EMBO Journal</i> , 1991, 111-1118, vol. 10, no. 5.
OB	SAKANO, S., et al., "Characterization Of A Ligand For Receptor Protein-Tyrosine Kinase HTK Expressed In Immature Hematopoietic Cells," <i>Oncogene</i> , 1996, 813-822, vol. 13.
OC	SASAKI, H., et al., "Serum Level Of The Periostin, A Homologue Of An Insect Cell Adhesion Molecule, In Thymoma Patients," <i>Cancer Letters</i> , 2001, 37-42, vol. 172.
OD	SAUDEK, C., et al., "A Preliminary Trial Of the Programmable Implantable Medication System For Insulin Delivery," <i>The New England Journal of Medicine</i> , 1989, 574-579, vol. 321, no. 9..
OE	SCHEIFFELE, P., et al., "Neuroigin Expressed In Nonneuronal Cells Triggers Presynaptic Development In Contacting Axons," <i>Cell</i> , 2000, 657-669, vol. 101.
OF	SHALABY, M., et al., "Development Of Humanized Bispecific Antibodies Reactive With Cytotoxic Lymphocytes And Tumor cells Overexpressing The HER2 Protooncogene," <i>J. Exp. Med.</i> , 1992, 217-225, vol. 175.
OG	SHARK, K., et al., "Cloning, Sequencing And Localization To Chromosome 11 Of A cDNA Encoding A Human Opioid-binding Cell Adhesion Molecule (OBCAM)," <i>Gene</i> , 1995, 213-217, vol. 155.
OH	SHAW, L., et al., "Activation Of Phosphoinositide 3-OH Kinase By The $\alpha 6\beta 4$ Integrin Promotes Carcinoma Invasion," <i>Cell</i> , 1997, 949-960, vol. 91.
OI	SHEA, R., et al., "Synthesis, Hybridization Properties And Antiviral Activity Of Lipid-Oligodeoxynucleotide Conjugates," <i>Nucleic Acids Research</i> , 1990, 3777-3783, vol. 18, no. 13.
OJ	SHIBUYA, K., et al., "Decay-Accelerating Factor Functions As A Signal Transducing Molecule For Human Monocytes," <i>The Journal of Immunology</i> , 1992, 1758-1762, vol. 149.

EXAMINER:		DATE CONSIDERED:	12/14/05
-----------	---	------------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). <sup>1</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>2</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>5</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO

**Complete if Known**

Application Number	10/696,639
Filing Date	10/29/2003
First Named Inventor	Maureen J. Bourner
Art Unit	1632
Examiner Name	TBA
Attorney Docket Number	PC27428A

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

OK	SHIMOYAMA, Y., et al., "Cadherin Cell-Adhesion Molecules In Human Epithelial Tissues And Carcinomas," <i>Cancer Research</i> , 1989, 2128-2133, vol. 49.
OL	SHIMOYAMA, Y., et al., "Molecular Cloning Of A Human Ca <sup>2+</sup> -Dependent Cell-Cell Adhesion Molecule Homologous To Mouse Placental Cadherin: Its Low Expression In Human Placental Tissues," <i>Journal Of Cell Biology</i> , 1989, 1787-1794, vol. 109.
OM	SHOPES, B., et al., "A Genetically Engineered Human IgG Mutant With Enhanced Cytolytic Activity," <i>The Journal of Immunology</i> , 1992, 1918-2922, vol. 148, no. 9.
ON	SIDMAN, K., et al., "Controlled Release Of Macromolecules And Pharmaceuticals From Synthetic Polypeptides Based On Glutamic Acid," <i>Biopolymers</i> , 1983, 547-556, vol. 22.
OO	SILVA, F., et al., "MUC1 Gene Polymorphism In The Gastric Carcinogenesis Pathway," <i>European Journal of Human Genetics</i> , 2001, 548-552, vol. 9.
OP	SKINNER, R., et al., "Use Of The Glu-Glu-Phe C-Terminal Epitope For Rapid Purification Of The Catalytic Domain Of Normal And Mutant ras GTPase-Activating Proteins," <i>The Journal of Biological Chemistry</i> , 1991, 14163-14166, vol. 266, no. 22.
OQ	SOMPAYRAC, L., et al., "Efficient Infection Of Monkey Cells With DNA Of Simian Virus 40," <i>Proc. Natl Acad Sci. USA</i> , 1981, 7575-7578, vol. 78, no 12.
OR	STEVENSON, G., et al., "A Chimeric Antibody With Dual Fc Regions (bisFabFc) Prepared By Manipulations At The IgG Hinge," <i>Anti-Cancer Drug Design</i> , 1989, 219-230, vol. 3.
OS	SURESH, M., et al., "Bispecific monoclonal Antibodies From Hybrid Hybridomas," <i>Methods In Enzymology</i> , 1986, 210-228, vol. 121.
OT	SUZUKI, S., et al., "Amino Acid Sequence Of A Novel Integrin $\beta_4$ Subunit And Primary Expression Of The mRNA In Epithelial Cells," <i>The EMBO Journal</i> , 1990, 757-763, vol. 9, no. 3.
OU	SVINARCHUK, F., et al., "Inhibition Of HIV Proliferation In MT-4 Cells By Antisense Oligonucleotide Conjugated To Lipophilic Groups," <i>Biochimie</i> , 1993, 49-54, vol. 75.
OV	SWISSHELM, K., "SEMP1, A Senescence-Associated cDNA Isolated From Human Mammary Epithelial Cells, Is A Member Of An Epithelial Membrane Protein Superfamily," <i>Gene</i> , 1999, 285-295, vol. 226.
OW	TAKASU, M., et al., "Modulation Of NMDA Receptor-Dependent Calcium Influx And Gene Expression Through EphB Receptor," <i>Science</i> , 2002, 491-495, vol. 295.
OX	TANG, X., et al., "Molecular Characterization And Chromosomal Localization Of DRT (EPHT3): A Developmentally Regulated Human Protein-Tyrosine Kinase Gene Of The EPH Family," <i>Human Molecular Genetics</i> , 1995, 2033-2045, vol. 4, no. 11.

EXAMINER:

DATE CONSIDERED:

12/14/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kindof document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**Complete if Known**

Application Number	10/696,639
Filing Date	10/29/2003
First Named Inventor	Maureen J. Bourner
Art Unit	1632
Examiner Name	TBA
Attorney Docket Number	PC27428A

**INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

OY	THIMMAPPAYA, B., et al., "Adenovirus VAI RNA Is required For Efficient Translation Of Viral mRNAs At Late Times After Infection," <i>Cell</i> , 1982, 543-551, vol. 31.
OZ	TOGO, S., et al., "Host Organ Specifically Determines Cancer Progression," <i>Cancer Research</i> , 1995, 681-684, vol. 55.
PA	TOMIZUKA, K., et al., "Double Trans-Chromosomal Mice: Maintenance Of Two Individual Human Chromosome Fragments Containing Ig Heavy And K Loci And Expression Of Fully Human Antibodies," <i>PNAS</i> , 2000, 722-727, vol. 97, no. 2.
PB	TRAUNECKER, A., et al., "Bispecific Single Chain Molecules (Janusins) Target Cytotoxic Lymphocytes On HIV Infected Cells," <i>The EMBO Journal</i> , 1991, 3655-3659, vol. 10, no. 12.
PC	TUSZYNSKI, G., et al., "Adhesive Proteins And The Hematogenous Spread Of Cancer," <i>Acta Haematologica</i> 1997, 29-39, vol. 97.
PD	TUTT, A., et al., "Trispecific F(ab') <sub>3</sub> Derivatives That Use Cooperative Signaling Via The TCR/CD3 Complex And CD2 To Activate And Redirect Resting Cytotoxic T Cells <sup>1</sup> ," <i>The Journal of Immunology</i> , 1991, 60-69, vol. 147, no. 1.
PE	UCHIDA, S., "Molecular Cloning Of The cDNA For An MDCK Cell Na <sup>+</sup> And Cl <sup>-</sup> -Dependent Taurine Transporter That Is regulated By Hypertonicity," <i>Proc. Nat. Acad. Sci.</i> , 1992, 8230-8234, vol. 89.
PF	VAN HAL, N., et al., "Monoclonal Antibody U36, A Suitable Candidate For Clinical Immunotherapy Of Squamous-cell Carcinoma, Recognizes A CD44 Isoform," <i>Int. J. Cancer</i> , 1996, 520-527, vol. 68.
PG	VENOOK, A., et al., "Gene Therapy Of Colorectal Liver Metastases Using A Recombinant Adenovirus Encoding WT P53 (SCH58500) Via Hepatic Artery Infusion: A Phase 1 Study," <i>Proceedings of ASCO</i> , 1998, 431a, vol. 17.
PH	VIDAL, F., et al., "Integrin β4 Mutations Associated With Junctional Epidermolysis Bullosa With Pyloric Atresia," <i>Nature Genetics</i> , 1995, 229-230, vol. 10.
PI	VIDAL, S., et al., "Cloning And Characterization Of A Second Human NRAMP Gene On chromosome 12q13," <i>Mammalian Genome</i> , 1995, 224-230, vol. 6.
PJ	VITETTA, E., et al., "Redesigning Nature's Poisons To Create Anti-Tumor Reagents," <i>Science</i> , 1987, 1098-1104, vol. 238.
PK	VOGELSTEIN, B., "Genetic Alterations During Colorectal-Tumor Development," <i>The New England Journal Of Medicine</i> , 1988, 525-532, vol. 319, no. 9.
PL	VOGELSTEIN, B., et al., "The Multistep Nature Of Cancer," <i>Trends In Genetics</i> , 1993, 138-141, vol. 9, no. 4.

EXAMINER:

DATE CONSIDERED:

12/14/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**Complete if Known**

Application Number	10/696,639
Filing Date	10/29/2003
First Named Inventor	Maureen J. Bourner
Art Unit	1632
Examiner Name	TBA
Attorney Docket Number	PC27428A

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Use as many sheets as necessary)

	PM	VOGT, T., et al., "Overexpression Of Lerk-5/Eplg5 Messenger RNA: A novel Marker For Increased Tumorigenicity And Metastatic Potential In Human Malignant Melanomas," <i>Clinical Cancer Research</i> , 1998, 791-797, vol 4.	
	PN	VOLLMERS, H., et al., "Adjuvant Therapy For Gastric Adenocarcinoma With The Apoptosis-Inducing Human Monoclonal Antibody SC-1: First Clinical And Histopathological Results," <i>Oncology Reports</i> , 1988, 549-552, vol. 5.	
	PO	WANG, D., et al., "Large-Scale Identification, Mapping, And Genotyping Of Single-Nucleotide Polymorphisms In The Human Genome," <i>Science</i> , 1998, 1077-1082, vol. 280.	
	PP	WANG, Q., et al., "Positional Cloning Of A Novel Potassium Channel Gene: <i>KVLQT1</i> Mutations Cause Cardiac Arrhythmias," <i>Nat Genet</i> , 1996, 17-23, vol. 12.	
	PQ	WANG, X., "Matrix Metalloproteinase Inhibitor BB-94 (Batinostat) Inhibits Human colon Tumor Growth And Spread In a Patient-Like Orthotopic Model In Nude Mice," <i>Cancer Research</i> , 1994, 4726-4728, vol. 54.	
	PR	WOLFF, E., et al., "Monoclonal Antibody Homodimers: Enhanced Antitumor Activity In Nude Mice," <i>Cancer Research</i> , 1993, 2560-2565, vol. 53.	
	PS	WU, G., et al., "Receptor-Mediated in Vitro Gene Transformation By A Soluble DNA Carrier System," <i>The Journal Of Biological Chemistry</i> , 1987, 4429-4432, vol. 262, no. 10.	
	PT	WU, X., et al., "Identity Of The Organic Cation Transporter OCT3 As The Extraneuronal Monoamine Transporter (uptake <sub>2</sub> ) And evidence For The Expression Of The Transporter In The Brain," <i>The Journal of Biological Chemistry</i> , 1998, 32776-32786, vol. 273, no. 49.	
	PU	XU, J., et al., "Molecular Cloning And functional Expression Of The bumetanide-Sensitive Na-K-Cl Cotransporter," <i>Proc. Natl Acad Sci</i> , 1994, 2201-2205, vol. 91.	
	PV	YAMAKAWA, M., et al., "Protection Of Thyroid Cancer Cells By Complement-Regulatory Factors," <i>Cancer</i> , 1994, 2808-2817, vol. 73, no. 11.	
	PW	ZACHARSKI, L., "Basis For Selection Of Anticoagulant Drugs For Therapeutic Trials In Human Malignancy," <i>Haemostasis</i> , 1986, 300-320, vol. 16.	
	PX	ZAPATA, G., et al., "Engineering Linear F(ab') <sub>2</sub> Fragments For Efficient Production In <i>Escherichia Coli</i> And Enhanced Antiproliferative Activity," <i>Protein Engineering</i> , 1995, 1057-1062, vol. 8, no. 10.	
	PY	ZENDMAN, A., et al., "TM7XN1, A Novel Human EGF-TM7-Like cDNA, Detected With mRNA Differential Display Using Human Melanoma Cell Line With Different Metastatic Potential," <i>FEBS Letters</i> , 1999, 292-298, vol. 446.	
	PZ	ZERVOS, A., et al., "Mxi1, A Protein That Specifically Interacts With Max To Bind Myc-Max Recognition Sites," <i>Cell</i> , 1993, 223-232, vol. 72.	

EXAMINER:

DATE CONSIDERED:

12/14/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
 (Use as many sheets as necessary)
**Complete if Known**

Application Number	10/696,639
Filing Date	10/29/2003
First Named Inventor	Maureen J. Bourner
Art Unit	1632
Examiner Name	TBA
Attorney Docket Number	PC27428A

	QA	ZWACKA, R., et al., "Gene Therapy For Colon Cancer," <i>Hematology/Oncology Clinics Of North America</i> , 1998, 585-615, vol. 12.	

EXAMINER:	DATE CONSIDERED:
	12/14/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kindof document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.